ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
루푸스 신염 시장 규모는 향후 수년간 강력한 성장이 예상될 예정입니다. 2029년에는 CAGR 7.6%로 성장할 전망이며, 28억 달러로 성장이 예측됩니다. 예측 기간 동안의 성장은 의사의 의식 고조, 생물학적 요법의 채용 확대, 전문 클리닉 증가, 신장 이식에 대한 중점화, 신장 내과 서비스에 대한 액세스 개선 등의 요인에 기인할 것으로 보입니다. 예측 기간 주요 동향으로는 생물학적 요법 진보, 맞춤형 의료에 대한 접근, 신규 진단 바이오마커 발견, 임상시험 확대, 줄기세포 치료 진보 등을 들 수 있습니다.
유전적 소인의 유병률 증가는 향후 루푸스 신염 시장의 성장을 견인할 것으로 예측됩니다. 유전적 소인은 특정 질환이나 병태를 발병하기 쉽게 하는 유전적 형질을 말합니다. 유전, 환경의 영향, 유전자 돌연변이 등의 요인이 유전적 소인의 유병률 상승에 기여하고 있습니다. 이 소인은 루푸스 신염의 개발에 주된 역할을 하고 있으며, 특히 신장 기능에 영향을 미치는 자가면역 질환에 있어서 유전적 요인의 영향에 하이라이트를 맞추고 있습니다. 예를 들어 2024년 10월 낭포성 섬유증 트러스트는 영국 CF 레지스트리가 2022년 1만 1,148명의 환자를 기록했고, 2024년에는 1만 1,318명으로 증가했다고 보고했습니다. 따라서 유전적 소인의 유병률 증가가 루푸스 신염 시장 성장에 기여하고 있습니다.
루푸스 신염 시장의 각사는 환자의 치료 성적과 장기적인 신장 기능을 개선하기 위해 선진적인 2세대 칼시뉴린 억제제의 개발에 주력하고 있습니다. 이러한 억제제는 루푸스 신염에서 면역 반응을 조절함으로써 염증을 억제하고 신장 장애를 예방하는 데 사용됩니다. 예를 들면, 2024년 9월, 아우리니어 제약 주식회사는, 루푸스 신염 치료약으로서 LUPKYNIS(일반명 보클로스포린)의 승인을 후생 노동성으로부터 취득했습니다. 이번 승인은 본 약제의 안전성 및 유효성을 실증한 아우로라 임상 프로그램의 양호한 결과를 바탕으로 미코페놀산 모페틸(MMF)과의 병용이 인정된 것입니다. 이번 승인은 일본 루푸스 신염 환자의 치료 선택지를 확대하고 질환 관리와 예후를 개선하는 데 큰 진전이 될 것입니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장-거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
세계의 루푸스 신염 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
최종 이용 산업의 분석
세계의 루푸스 신염 시장 : 성장률 분석
세계의 루푸스 신염 시장 실적 : 규모 및 성장(2019-2024년)
세계의 루푸스 신염 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
세계의 루푸스 신염 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 루푸스 신염 시장 : 스테이지별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
클래스 1
클래스 2
클래스 3
기타 스테이지
세계의 루푸스 신염 시장 : 약제 클래스별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
면역억제제
코르티코스테로이드
생물학적 인자
항말라리아 약
세계의 루푸스 신염 시장 : 투여 경로별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
오랄
비경구
기타 투여 경로
세계의 루푸스 신염 시장 : 유통 채널별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
병원 약국
소매 약국
온라인 약국
세계의 루푸스 신염 시장 : 최종 사용자별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
병원
전문 클리닉
기타 최종 사용자
세계의 루푸스 신염 시장 : 클래스 1별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
무증상의 증례
경도의 단백질 소변
우발적인 진단
세계의 루푸스 신염 시장 : 클래스 2별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
경도의 혈뇨
저도 단백질 소변
최소한의 면역 복합체 침착
세계의 루푸스 신염 시장 : 클래스 3별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
활동성 병변
만성 경화성 병변
초승달형
세계의 루푸스 신염 시장 : 기타 스테이지별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
클래스 4(분만성 루푸스 신염)
클래스 5(막성 루푸스 신염)
클래스 6(진행성 경화성 루푸스 신염)
제7장 지역별 및 국가별 분석
세계의 루푸스 신염 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
세계의 루푸스 신염 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
루푸스 신염 시장 : 경쟁 구도
루푸스 신염 시장 : 기업 프로파일
F. Hoffmann-La Roche Ltd. : 개요, 제품 및 서비스, 전략 및 재무 분석
Bristol Myers Squibb : 개요, 제품 및 서비스, 전략 및 재무 분석
Novartis AG : 개요, 제품 및 서비스, 전략 및 재무 분석
GlaxoSmithKline plc : 개요, 제품 및 서비스, 전략 및 재무 분석
Eli Lilly and Company : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Genentech
Astrazeneca PLC
Biocon Biologics
Hanmi Pharmaceutical Co. Ltd.
Sana Biotechnology Inc.
RemeGen Co. Ltd.
Aurinia Pharmaceuticals Inc.
Otsuka Pharmaceutical Co. Ltd.
Equillium Inc.
Anthera Pharmaceuticals Inc.
Atara Biotherapeutics Inc.
Artiva Biotherapeutics
Caribou Biosciences
Nkarta Inc.
Adicet Bio Inc.
제32장 세계 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
루푸스 신염 시장(2029년) : 새로운 기회를 제공하는 국가
루푸스 신염 시장(2029년) : 새로운 기회를 제공하는 부문
루푸스 신염 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
AJY
영문 목차
영문목차
Lupus nephritis is a severe kidney condition caused by systemic lupus erythematosus (SLE), an autoimmune disease in which the immune system erroneously attacks healthy tissues, including the kidneys. This inflammation can result in kidney damage, reduced function, and, if left untreated, potentially lead to kidney failure. Early diagnosis and treatment are essential for managing the disease effectively.
Lupus nephritis progresses through different stages, including class 1, class 2, class 3, and others. Class 1 represents a stage with minimal kidney damage, where kidney function remains stable, and symptoms are generally not apparent. Treatment at this stage focuses on preventing further progression of the disease. Common drug classes used in treatment include immunosuppressive drugs, corticosteroids, biological agents, and antimalarial drugs, which can be administered orally, parenterally, and through other routes. These treatments are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, with end users such as hospitals, specialty clinics, and others.
The lupus nephritis market research report is one of a series of new reports from The Business Research Company that provides lupus nephritis market statistics, including lupus nephritis industry global market size, regional shares, competitors with a lupus nephritis market share, detailed lupus nephritis market segments, market trends and opportunities, and any further data you may need to thrive in the lupus nephritis industry. This lupus nephritis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The lupus nephritis market size has grown strongly in recent years. It will grow from $1.94 billion in 2024 to $2.09 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth during the historic period can be attributed to factors such as increased research investments in lupus nephritis, a rising incidence of autoimmune diseases, higher healthcare spending, the growing adoption of biologics, and the increasing popularity of telemedicine.
The lupus nephritis market size is expected to see strong growth in the next few years. It will grow to $2.80 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The growth during the forecast period can be attributed to factors such as the rising awareness among physicians, greater adoption of biologic therapies, an increasing number of specialty clinics, a growing emphasis on renal transplantation, and improved access to nephrology services. Key trends in the forecast period include advancements in biologic therapies, personalized medicine approaches, the discovery of novel diagnostic biomarkers, an expansion of clinical trials, and progress in stem cell therapy.
The increasing prevalence of genetic predisposition is expected to drive the growth of the lupus nephritis market in the future. Genetic predisposition refers to inherited genetic traits that make an individual more likely to develop certain diseases or conditions. Factors such as inheritance, environmental influences, and gene mutations contribute to the rising prevalence of genetic predisposition. This predisposition plays a key role in the development of lupus nephritis, highlighting the influence of inherited genetic factors in autoimmune diseases, particularly those affecting kidney function. For example, in October 2024, the Cystic Fibrosis Trust reported that the UK CF Registry recorded 11,148 patients in 2022, which increased to 11,318 in 2024, reflecting a 1.52% rise in cystic fibrosis (CF) patients. Therefore, the growing prevalence of genetic predisposition is contributing to the growth of the lupus nephritis market.
Companies in the lupus nephritis market are focusing on developing advanced second-generation calcineurin inhibitors to improve treatment outcomes and long-term kidney function for patients. These inhibitors are used in lupus nephritis to reduce inflammation and prevent kidney damage by modulating immune responses. For example, in September 2024, Aurinia Pharmaceuticals Inc. received approval from the Japanese Ministry of Health, Labour, and Welfare for LUPKYNIS (voclosporin) as a treatment for lupus nephritis. This approval allows voclosporin to be used in combination with mycophenolate mofetil (MMF), based on the positive results from the AURORA Clinical Program, which demonstrated the drug's safety and efficacy. This approval marks a significant step forward in expanding treatment options for lupus nephritis patients in Japan, improving both disease management and outcomes.
In March 2024, Lupus Therapeutics, an affiliate clinical research partner of the Lupus Research Alliance, partnered with Artiva Biotherapeutics Inc. to support a clinical trial for lupus nephritis. This collaboration aims to conduct a Phase 1 trial to evaluate Artiva's AlloNK therapy with anti-CD20 antibodies for patients with active lupus nephritis. The trial will assess the safety and effectiveness of this potential treatment for this severe kidney complication. Artiva Biotherapeutics is a biotechnology company based in the US that develops treatments for lupus nephritis.
Major players in the lupus nephritis market are F. Hoffmann-La Roche Ltd., Bristol Myers Squibb, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Genentech, Astrazeneca PLC, Biocon Biologics, Hanmi Pharmaceutical Co. Ltd., Sana Biotechnology Inc., RemeGen Co. Ltd., Aurinia Pharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd., Equillium Inc., Anthera Pharmaceuticals Inc., Atara Biotherapeutics Inc., Artiva Biotherapeutics, Caribou Biosciences, Nkarta Inc., Adicet Bio Inc., Lupus Research Alliance, Kyverna Therapeutics Inc., Kezar Life Sciences, and Bionxt Solutions.
Asia-Pacific was the largest region in the lupus nephritis market in 2024. The regions covered in lupus nephritis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the lupus nephritis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The lupus nephritis market consists of revenues earned by entities by providing services such as dialysis services, diagnostic testing, renal care services, and home healthcare services. The market value includes the value of related goods sold by the service provider or included within the service offering. The lupus nephritis market also consists of sales of medical devices, diagnostic products, and renal replacement products. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Lupus Nephritis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on lupus nephritis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for lupus nephritis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The lupus nephritis market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Stage: Class 1; Class 2; Class 3; Other Stages
2) By Drug Class: Immunosuppressive Drugs; Corticosteroids; Biological Agents; Antimalarial Drugs
3) Route Of Administration: Oral; Parenteral; Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
5) By End-User: Hospitals; Specialty Clinics; Other End-Users
Subsegments:
1) By Class 1: Asymptomatic Cases; Mild Proteinuria; Incidental Diagnosis.
2) By Class 2: Mild Hematuria; Low-Grade Proteinuria; Minimal Immune Complex Deposition.
3) By Class 3: Active Lesions; Chronic Sclerotic Lesions; Crescent Formation.
4) By Other Stages: Class 4 (Diffuse Lupus Nephritis); Class 5 (Membranous Lupus Nephritis); Class 6 (Advanced Sclerotic Lupus Nephritis)
Companies Mentioned: F. Hoffmann-La Roche Ltd.; Bristol Myers Squibb; Novartis AG; GlaxoSmithKline plc; Eli Lilly and Company
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Lupus Nephritis Market Characteristics
3. Lupus Nephritis Market Trends And Strategies
4. Lupus Nephritis Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Lupus Nephritis Growth Analysis And Strategic Analysis Framework
5.1. Global Lupus Nephritis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Lupus Nephritis Market Growth Rate Analysis
5.4. Global Lupus Nephritis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Lupus Nephritis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Lupus Nephritis Total Addressable Market (TAM)
6. Lupus Nephritis Market Segmentation
6.1. Global Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Class 1
Class 2
Class 3
Other Stages
6.2. Global Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immunosuppressive Drugs
Corticosteroids
Biological Agents
Antimalarial Drugs
6.3. Global Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Parenteral
Other Routes Of Administration
6.4. Global Lupus Nephritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
6.5. Global Lupus Nephritis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Speciality Clinics
Other End-Users
6.6. Global Lupus Nephritis Market, Sub-Segmentation Of Class 1, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Asymptomatic Cases
Mild Proteinuria
Incidental Diagnosis
6.7. Global Lupus Nephritis Market, Sub-Segmentation Of Class 2, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Mild Hematuria
Low-Grade Proteinuria
Minimal Immune Complex Deposition
6.8. Global Lupus Nephritis Market, Sub-Segmentation Of Class 3, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Active Lesions
Chronic Sclerotic Lesions
Crescent Formation
6.9. Global Lupus Nephritis Market, Sub-Segmentation Of Other Stages, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Class 4 (Diffuse Lupus Nephritis)
Class 5 (Membranous Lupus Nephritis)
Class 6 (Advanced Sclerotic Lupus Nephritis)
7. Lupus Nephritis Market Regional And Country Analysis
7.1. Global Lupus Nephritis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Lupus Nephritis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Lupus Nephritis Market
8.1. Asia-Pacific Lupus Nephritis Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Lupus Nephritis Market
9.1. China Lupus Nephritis Market Overview
9.2. China Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Lupus Nephritis Market
10.1. India Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Lupus Nephritis Market
11.1. Japan Lupus Nephritis Market Overview
11.2. Japan Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Lupus Nephritis Market
12.1. Australia Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Lupus Nephritis Market
13.1. Indonesia Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Lupus Nephritis Market
14.1. South Korea Lupus Nephritis Market Overview
14.2. South Korea Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Lupus Nephritis Market
15.1. Western Europe Lupus Nephritis Market Overview
15.2. Western Europe Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Lupus Nephritis Market
16.1. UK Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Lupus Nephritis Market
17.1. Germany Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Lupus Nephritis Market
18.1. France Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Lupus Nephritis Market
19.1. Italy Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Lupus Nephritis Market
20.1. Spain Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Lupus Nephritis Market
21.1. Eastern Europe Lupus Nephritis Market Overview
21.2. Eastern Europe Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Lupus Nephritis Market
22.1. Russia Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Lupus Nephritis Market
23.1. North America Lupus Nephritis Market Overview
23.2. North America Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Lupus Nephritis Market
24.1. USA Lupus Nephritis Market Overview
24.2. USA Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Lupus Nephritis Market
25.1. Canada Lupus Nephritis Market Overview
25.2. Canada Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Lupus Nephritis Market
26.1. South America Lupus Nephritis Market Overview
26.2. South America Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Lupus Nephritis Market
27.1. Brazil Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Lupus Nephritis Market
28.1. Middle East Lupus Nephritis Market Overview
28.2. Middle East Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Lupus Nephritis Market
29.1. Africa Lupus Nephritis Market Overview
29.2. Africa Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Lupus Nephritis Market Competitive Landscape And Company Profiles
